Catastrophic Antiphospholipid Syndrome

  • H. M. Belmont


The syndrome of multiple vascular occlusions associated with high titer antiphospholipid antibodies (aPL) is known as the catastrophic antiphospholipid syndrome (APS). Although APS is typically characterized by thrombotic events that either occur singly or, when recurrent, are seen many months or even years apart, some patients with this syndrome may develop widespread, non-inflammatory vascular occlusions. The prevalence and incidence of this condition both in the general population, as well as those with SLE or antiphospholipid antibodies, is unknown. However, expanding numbers of patients fulfilling criteria for catastrophic APS are now reported which reflects increasing familiarity with the disorder.


Systemic Lupus Erythematosus Systemic Inflammatory Response Syndrome Thrombotic Thrombocytopenic Purpura Adult Respiratory Distress Syndrome Membrane Attack Complex 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Dosekun AK, Pollak VE, Glas-Greenwalt P, et al. Ancrod in systemic lupus erythematosus with thrombosis. Clinical and firbrinolytic effects. Arch Intern Med 1984; 144: 37–42.PubMedCrossRefGoogle Scholar
  2. 2.
    Ingram SB, Goodnight SH, Bennett RH. An unusual syndrome of a devastating non-inflammatory vasculopathy associated with anticardiolipin antibodies. Arthritis Rheum, 1987; 30: 1167–1171.PubMedCrossRefGoogle Scholar
  3. 3.
    Greisman SG, Thayaparan R-S, Godwin TA, Lockshin MD. Occlusive vasculopathy in systemic lupus erythematosus-Association with anticardiolipin antibody. Arch Intern Med 1991; 151: 389–392.PubMedCrossRefGoogle Scholar
  4. 4.
    Harris EN and K Bos. An acute disseminated coagulopathy-vasculopathy associated with the antiphospholipid syndrome. Arch Intern Med 1991; 151: 231–232.PubMedCrossRefGoogle Scholar
  5. 5.
    Asherson RA. The catastrophic antiphospholipid syndrome. J. Rheumatol 1992; 19: 508–512.PubMedGoogle Scholar
  6. 6.
    Asherson RA, Cervera R, Piette J-C, Font J, Lie JT, Burcoglu A, et al. Catastrophic antiphospholipid syndrome: Clinical and laboratory features of 50 patients. Medicine 1998; 77: 195–207.PubMedCrossRefGoogle Scholar
  7. 7.
    Le Loet X, Vittecoq O, Joen-Beades F, Tron F. Catastrophic antiphospholipid syndrome. Presse Medicale 1997; 26: 131–134.Google Scholar
  8. 8.
    Petras T, Rudolph B, Filler G, Zimmering M, Ditscherlein G, Loening SA. An adolescent with acute renal failure, thrombocytopenia and femoral vein thrombosis. Nephrology, Dialysis, Transplantation 1998; 13: 480–483.Google Scholar
  9. 9.
    Falcini F, Taccetti G, Ermini M, Trapani S, Matucci Cerinic M. Catastrophic antiphospholipid antibody syndrome in pediatric systemic lupus erythematosus. J Rheumatol 1997; 24: 389–392.PubMedGoogle Scholar
  10. 10.
    Provenzale JM, Spritzer CE, RC Nelson, TL Ortel. Disseminated thrombosis in primary antiphospholipid syndrome: MR findings. Eur J of Radiol 1998; 26: 244–247.CrossRefGoogle Scholar
  11. 11.
    Argento A, DiBenedetto RJ. ARDS and adrenal insufficiency associated with the antiphospholipid antibody syndrome. Chest 1998; 113: 1136–1138.PubMedCrossRefGoogle Scholar
  12. 12.
    Dasgupta B, Almond MK, Tanqueray A. Polyarteritis nodosa and the antiphospholipid syndrome. Br J Rheumatol 1997; 36: 1210–1212.PubMedCrossRefGoogle Scholar
  13. 13.
    Chinnery PF, Shaw PJ, Ince PG, Jackson GH, Bishop RI. Fulminant encephalopathy due to the catastrophic primary antiphospholipid syndrome (letter). J Neurol Neurosurg Psych 1997; 62: 300–301.CrossRefGoogle Scholar
  14. 14.
    Kane D, McSweeney F, Swan N, Bresnihan B. Catastrophic antiphospholipid antibody syndrome in primary systemic sclerosis. J Rheumatol 1998; 25: 810–812.PubMedGoogle Scholar
  15. 15.
    Neuwelt CM, Daikh DI, Linfoot JA, Pfister DA, Young RG, Webb RL, et al. Catastrophic antiphospholipid syndrome. Response to repeated plasmapheresis over three years. Arthritis Rheum 1997; 40: 1534–1539.PubMedCrossRefGoogle Scholar
  16. 16.
    Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GRV. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332: 993–997.PubMedCrossRefGoogle Scholar
  17. 17.
    Yu Z, Lennon VA. Clinical implications of basic research: mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 1999; 340: 227–228.PubMedCrossRefGoogle Scholar
  18. 18.
    Kitchens C. Thrombotic storm. Am J Med 1998; 164: 381.CrossRefGoogle Scholar
  19. 19.
    Belmont HM, Abramson SB, Lie JT. Pathology and pathogenesis of vascular injury in systemic lupus erythematosus. Interactions of inflammatory cells and activated endothelium. Arthritis Rheum 1996; 39: 9–22.Google Scholar
  20. 20.
    Golden BD, Belmont HM. The role of microvasculopathy in the catastrophic antiphospholipid syndrome: comment on the article by Neuwelt et al (letter). Arthritis Rheum 1997; 40: 1534–1539.CrossRefGoogle Scholar
  21. 21.
    Abramson SA, Belmont HM. SLE: mechanisms of vascular injury. Hospital Practice 1998; 33: 107–127.PubMedCrossRefGoogle Scholar
  22. 22.
    Tsai H-M, Lian EC-Y. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339: 1585–1594.PubMedCrossRefGoogle Scholar
  23. 23.
    Cockwell P, Tse WY, Savage CO. Activation of endothelial cells in thrombosis and vasculitis. Scan J Rheumatol 1997; 26: 145–150.CrossRefGoogle Scholar
  24. 24.
    Arnaout MA, Colten HR. Complement C3 receptors: structure and function. Molec. Immun. 1984; 21: 1191–1199.PubMedCrossRefGoogle Scholar
  25. 25.
    Kilgore KS, Shen JP, Miller BF, Ward PA, Warren JS. Enhancement by the complement membrane attack complex of tumor necrosis factor-alpha-induced endothelial cell expression of E-selectin and ICAM-1. J Immunol 1995; 155: 1434.PubMedGoogle Scholar
  26. 26.
    Lozada C, Levin RI, Huie M, Hirschhorn R, Naime D, Whitlow M, et al. Identification of Clq as the heat-labile serum cofactor required for immune complexes to stimulate endothelial expression of the adhesion molecules E-selectin and intercellular and vascular cell adhesion molecules. Proc Natl Acad Sci USA 1995; 92: 8378–8382.PubMedCrossRefGoogle Scholar
  27. 27.
    Neng Lai LK, Leung JC, Bit Lai K, Li PK, Lai CK. Anti-DNA autoantibodies stimulate the release of interleukin-1 and interleukin-6 from human endothelial cells. J Pathol 1996; 178: 451–458.PubMedCrossRefGoogle Scholar
  28. 28.
    Lai KN, Leung JC, Lai KB, Wong KC, Lai CK. Upregulation of adhesion molecule expression on endothelial cells by anti-DNA autoantibodies in systemic lupus erythematosus. Clin Immunol I m m u n o p a t h o l 1996; 81: 229–238.Google Scholar
  29. 29.
    Simantov R, LaSala J, Lo SK, Gharavi A, Sammaritano LR, Salmon JE, et al. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest 1995; 96: 2211–2219.PubMedCrossRefGoogle Scholar
  30. 30.
    Bone RC. Why new definitions of sepsis and organ failure are needed. Am J Med 1993; 95: 348.PubMedCrossRefGoogle Scholar
  31. 31.
    Nogare D. Septic shock. Am J Med Sci 1991; 302: 50–65.CrossRefGoogle Scholar
  32. 32.
    Waage A, Brandtzaeg P, Espevik T, Halstensen A. Current understanding of the pathogenesis of gram-negative shock. Infect Dis Clin North Am 1991; 5: 781–789.PubMedGoogle Scholar

Copyright information

© Springer-Verlag London 2000

Authors and Affiliations

  • H. M. Belmont

There are no affiliations available

Personalised recommendations